CoChat

Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis

Open access
Guirguis, A, Chiappini, S, Papanti P, GD, Vickers-Smith, R., Harris, D, Corkery, JM, Arillotta, D, Floresta, G., Martinotti, G, Schifano, F · 2024 · European Neuropsychopharmacology
Cited by 65

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). AIM: The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators. METHODS: Descriptive and pharmacovigilance disproportionality analyses was performed. RESULTS: A total of 209,354 ADRs were reported, including 59,300 serious cases. Of those, a total of 5378 psychiatric disorder cases, including 383 'serious' cases related to selected ADRs were registered during 2005-2023. After unmasking, 271 cases where individual GLP-1 RA were implicated showing liraglutide (n = 90; Reported Odds Ratio (ROR) = 1.64), exenatide (n = 67; ROR = 0.80), semaglutide (n = 61; ROR = 2.03), dulaglutide (n = 45; ROR = 0.84), tirzepatide (n = 5; ROR = 1.76) and albiglutide (n = 2; ROR = 0.04). A greater association between these ADRs with metformin was observed, but not orlistat. With regards to selected preferred terms (PTs), 42 deaths including 13 completed suicides were recorded. Suicidal ideation was recorded in n = 236 cases for 6/7 GLP-1 RA (excluding lixisenatide). DISCUSSION: Suicide/self-injury reports pertaining to semaglutide; tirzepatide; and liraglutide were characterised, although lower than metformin. It is postulated that rapid weight loss achieved with GLP-1 RA can trigger significant emotional, biological, and psychological responses, hence possibly impacting on suicidal and self-injurious ideations. CONCLUSIONS: With the current pharmacovigilance approach, no causality link between suicidal ideation and use of any GLP-1 RA can be inferred. There is a need for further research and vigilance in GLP-1 RA prescribing, particularly in patients with co-existing psychiatric disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2024.02.003

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 36

  1. Ahrén, 2011, GLP-1 for type 2 diabetes, Exp. Cell Res., 317, 1239, 10.1016/j.yexcr.2011.01.010 · DOI
  2. Anderberg, 2014, Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior, Physiol. Behav., 136, 135, 10.1016/j.physbeh.2014.02.026 · DOI
  3. Baldini, 2023, The possible role of prescribing medications, including central nervous system drugs, in contributing to male-factor infertility (MFI): assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database, Brain Sci., 13, 1652, 10.3390/brainsci13121652 · DOI
  4. Bihan, 2020, Uses of pharmacovigilance databases: an overview, Therapies, 75, 591, 10.1016/j.therap.2020.02.022 · DOI · Paper page
  5. Boekholdt, 2010, Rimonabant: obituary for a wonder drug, Lancet, 376, 489, 10.1016/S0140-6736(10)61080-X · DOI
  6. Capogrosso Sansone, 2017, Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian national network of pharmacovigilance database, Drug Saf., 40, 895, 10.1007/s40264-017-0564-8 · DOI
  7. Chen, 2023, Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis, Eur. Psychiatry, 66, 10.1192/j.eurpsy.2023.2474 · DOI · Paper page
  8. Chiappini, S., Vickers-Smith, R., Papanti, D.G., Corkery, J.M., Guirguis, A., Martinotti, G., Sensi, S.L. and Schifano, F., 2023. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. 2023 Jul 11;16(7), 994. · DOI · Paper page
  9. Çiçekli, 2022, GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway, J. Recept. Signal Transduction Res., 42, 486, 10.1080/10799893.2022.2032747 · DOI
  10. Corazza, 2019, The emergence of Exercise Addiction, Body Dysmorphic Disorder, and other image-related psychopathological correlates in fitness settings: a cross-sectional study, PLoS ONE, 14, 10.1371/journal.pone.0213060 · DOI · Paper page
  11. Engelberg, 1992, Low serum cholesterol and suicide, Lancet, 339, 727, 10.1016/0140-6736(92)90609-7 · DOI · Paper page
  12. Faillie, 2019, Case–non-case studies: principles, methods, bias, and interpretation, Therapies, 74, 225, 10.1016/j.therap.2019.01.006 · DOI · Paper page
  13. Gawin, 1991, Cocaine addiction: psychology and neurophysiology, Science, 251, 1580, 10.1126/science.2011738 · DOI · Paper page
  14. Gawin, 1991, Correction: cocaine addiction: psychology and neuropsychology, Science, 253, 10.1126/science.253.5019.494.f · doi:10.1126/science.253.5019.494.f
  15. Gilbert, 2020, GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials, Front. Endocrinol. (Lausanne), 11, 178, 10.3389/fendo.2020.00178 · DOI · Paper page
  16. Hanna, 2015, The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health, Expert. Rev. Endocrinol. Metab., 10, 101, 10.1586/17446651.2015.972370 · DOI
  17. Isacson, 2011, The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test, Is Eur. J. Pharmacol., 650, 249, 10.1016/j.ejphar.2010.10.008 · DOI
  18. Ma, 2023, GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicity, Heliyon., 9, e18491, 10.1016/j.heliyon.2023.e18491 · DOI
  19. Maignen, 2014, Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases, Pharmacoepidemiol. Drug Saf., 23, 195, 10.1002/pds.3529 · doi:10.1002/pds.3529
  20. Mansur, 2018, Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists?, Neuropharmacology, 136, 335, 10.1016/j.neuropharm.2018.01.048 · DOI · Paper page
  21. Melis, 2007, The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food, Neurosci. Lett., 419, 231, 10.1016/j.neulet.2007.04.012 · DOI
  22. Mitchell, 2007, Depression and anxiety with rimonabant, Lancet, 370, 1671, 10.1016/S0140-6736(07)61705-X · DOI
  23. Mitchell, 2013, Possible risk factors for increased suicide following bariatric surgery, Obesity, 21, 665, 10.1002/oby.20066 · DOI · Paper page
  24. Montastruc, 2011, Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, Br. J. Clin. Pharmacol., 72, 905, 10.1111/j.1365-2125.2011.04037.x · DOI · Paper page
  25. Nazeem, 2021, Saxagliptin ameliorated the depressive-like behavior induced by chronic unpredictable mild stress in rats: impact on incretins and AKT/PI3K pathway, Eur. J. Pharmacol., 912, 10.1016/j.ejphar.2021.174602 · DOI
  26. Phillips, 2007, Suicidality in body dysmorphic disorder, Prim. Psychiatry, 14, 58
  27. Robertson, 2009, Drugs associated with more suicidal ideations are also associated with more suicide attempts, PLoS ONE, 4, 10.1371/journal.pone.0007312 · DOI
  28. Ruggiero, 2024, Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European pharmacovigilance database, Pharmaceuticals, 17, 147, 10.3390/ph17020147 · DOI · Paper page
  29. Seo, 2023, Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test, J. Affect. Disord., 324, 8, 10.1016/j.jad.2022.12.089 · DOI · Paper page
  30. Sharma, 2015, GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats, Metab. Brain Dis., 30, 519, 10.1007/s11011-014-9591-7 · DOI · Paper page
  31. Tomson-Johanson, 2020, Low cholesterol levels in children predict impulsivity in young adulthood, Acta Neuropsychiatr., 32, 196, 10.1017/neu.2019.48 · DOI
  32. Van Gaal, 2008, Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program, Diabetes Care, 31, S229, 10.2337/dc08-s258 · DOI · Paper page
  33. Veale, 2001, Mirror, mirror on the wall, who is the ugliest of them all? The psychopathology of mirror gazing in body dysmorphic disorder, Behav. Res. Ther., 39, 1381, 10.1016/S0005-7967(00)00102-9 · DOI · Paper page
  34. Verovnik, 2024, Semaglutide, suicidal ideation and behaviour: a resting state functional magnetic resonance imaging perspective, Diabetes Obes. Metabol., 26, 10.1111/dom.15363 · DOI
  35. Wisłowska-Stanek, 2021, Neurobiological basis of increased risk for suicidal behaviour, Cells, 10, 2519, 10.3390/cells10102519 · DOI · Paper page
  36. Yau, 2013, Stress and eating behaviors, Minerva Endocrinol., 38, 255

Cited by

See all 65

Metadata

Authors
Guirguis, A., Chiappini, S., Papanti P, G., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F.
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2024-05
Volume
82
Pages
82-91
ISSN
0924-977X (ISSN-L)
OpenAlex
W4392936204
Cited by
65
References
22
FWCI
49.08
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Swansea University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. https://app.cochat.ai/papers/10.1016/j.euroneuro.2024.02.003
The paper
Guirguis, A., Chiappini, S., Papanti P, G., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2024.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.